A recent study has revealed that older patients with myopic choroidal neovascularization (mCNV) have poorer vision than their younger counterparts and are more likely to develop concomitant vitreoretinal interface abnormalities (VIA).
 |
| Photo: Myopic Choroidal Neovascularization | InStyleHealth |
What is mCNV or Myopic Choroidal Neovascularization?
Myopic choroidal neovascularization (mCNV)
is one of the most dreaded complications of high myopia – defined as an axial
length greater than 26.5 mm or refractive error greater than -6 D. This is
where the eye progressively lengthens from front to back and degenerates, and
neovascularization develops.
It is now established that myopic CNV can occur in patients
with any degree of myopia, even in the absence of characteristic degenerative
retinal changes.
Researchers of this study said, “In addition, baseline
best-corrected visual acuity (BCVA), external limiting membrane (ELM), CNV
lesion size, and CNV lesion location were correlated with BCVA after 1 year of
conbercept therapy. Baseline central macular thickness (CMT) may be a predictor
of relapse in older mCNV patients during the one-year follow-up.”
There were 64 eyes from 64 newly diagnosed CNV
patients with an average age of 51 years, 67.2% women were subjected in this
study. There were 39 aged greater than 50 years, and the remaining 25 were
younger patients.
In the older group, 21 patients had 12-month follow-up
data available and were included in further research analyses. VIA was significantly
more visualized in the older group, according to Fisher’s exact test. Average
BCVA was higher in the older group and sub foveal choroidal thickness (SFCT)
was lower.
By utilizing the stepwise multivariate regression
analysis, it was found that baseline BCVA and ELM integrity were significant
and independent prognostic factors of final BCVA after 12 months of follow-up.
The mCNV recurrence was detected in 7 of the 21
elderly patients (33.3%), occurring after an average of 9.4 months after the first
injection. Higher baseline CMT was a significant predictor of recurrence.
For a complete view of the clinical research, you may click
here.
Source: Sci Rep 2021;11:7337